```html

Zollinger‑Ellison Refractory Ulcer Disease: A Patient‑Focused Guide

Overview

Zollinger‑Ellison syndrome (ZES) is a rare disorder in which one or more gastrin‑producing tumors (gastrinomas) develop in the pancreas or duodenum. These tumors secrete excessive gastrin, a hormone that stimulates the stomach to produce large amounts of acid. When the acid output overwhelms the protective mechanisms of the gastrointestinal (GI) tract, patients develop multiple, severe peptic ulcers that are refractory—meaning they do not heal with standard ulcer therapy such as proton‑pump inhibitors (PPIs) or H2‑receptor antagonists.

Who it affects: ZES can occur at any age but most commonly presents in the 30‑ to 60‑year‑old range. Both men and women are affected, although a slight male predominance (~55 % of cases) has been reported.<sup>1</sup> Approximately 20‑30 % of patients with ZES have multiple endocrine neoplasia type 1 (MEN 1), a hereditary condition that predisposes to gastrinomas, pituitary tumors, and hyperparathyroidism.

Prevalence: Gastrinomas are rare, with an estimated incidence of 0.5–2 per million persons per year and a prevalence of roughly 1–3 per 100,000.<sup>2</sup> Because the disease is uncommon and often misdiagnosed, the true prevalence of refractory ulcer disease secondary to ZES may be slightly higher.

Symptoms

Symptoms stem from two main mechanisms: (1) hyperacidic damage to the GI mucosa and (2) mass effects of the tumor itself.

• Recurrent or persistent abdominal pain – usually epigastric, burning, or cramping; may improve with meals (duodenal ulcer) or worsen (gastric ulcer).
• Diarrhea or steatorrhea – excess acid inactivates pancreatic enzymes, leading to fat malabsorption.
• Heartburn or gastro‑esophageal reflux disease (GERD) – frequent, severe, and unresponsive to OTC antacids.
• Nausea and vomiting – sometimes with food intolerance.
• Weight loss – secondary to malabsorption, chronic pain, or anorexia.
• Gastrointestinal bleeding – melena or hematemesis from ulcer erosion.
• Perforation – sudden, severe abdominal pain with signs of peritonitis.
• Obstruction – due to ulcer scarring or tumor growth causing duodenal or biliary blockage.
• Symptoms from tumor metastasis – liver pain (hepatic spread), jaundice (biliary obstruction), or bone pain (osseous metastases).

Causes and Risk Factors

Primary cause

ZES is caused by gastrin‑secreting neuroendocrine tumors (gastrinomas). The majority (≈70 %) are located in the duodenum; the remainder are in the pancreas or, rarely, ectopic sites. These tumors are usually sporadic, but in ≈25 % of cases they are part of MEN 1, an autosomal‑dominant mutation of the MEN1 gene (encoding menin).

Risk factors

• Genetic predisposition: Having MEN 1 or a first‑degree relative with a gastrinoma.
• Age: Incidence rises after the third decade.
• Sex: Slight male predominance.
• Chronic H. pylori infection: While not a direct cause, it can mask ZES and delay diagnosis.
• Prolonged use of acid‑suppressive therapy without proper work‑up: May hide symptoms and postpone definitive testing.

Diagnosis

Diagnosing ZES requires a combination of biochemical, imaging, and endoscopic studies to confirm hypergastrinemia, acid hypersecretion, and to locate the tumor.

1. Laboratory Tests

• Fasting serum gastrin level: A level > 1000 pg/mL (ten‑fold above normal) is highly suggestive. Levels between 150–1000 pg/mL require a secretin stimulation test.
• Secretin stimulation test: In gastrinoma patients, gastrin paradoxically rises ≥ 120 pg/mL after IV secretin.
• Basal gastric pH: A pH < 2 confirms acid hypersecretion.
• Chromogranin A (CgA): Elevated in many neuroendocrine tumors; useful for monitoring.

2. Endoscopic Evaluation

• Upper endoscopy (EGD): Visualizes multiple ulcers, especially beyond the duodenal bulb, and allows biopsy to rule out H. pylori or malignancy.
• Endoscopic ultrasound (EUS): Highly sensitive for detecting small duodenal or pancreatic gastrinomas (< 1 cm).

3. Imaging Studies

• Multiphasic contrast‑enhanced CT or MRI: First‑line cross‑sectional imaging for tumor localization and metastasis assessment.
• Somatostatin receptor scintigraphy (Octreoscan) or Ga‑68 DOTATATE PET/CT: Gold standard for detecting occult or metastatic neuroendocrine tumors.
• Selective arterial secretin stimulation test (SASS): Invasive but highly accurate for pinpointing small duodenal gastrinomas.

Diagnostic criteria summary

1. Fasting gastrin > 1000 pg/mL OR positive secretin test.
2. Evidence of gastric acid hypersecretion (pH < 2 or high basal acid output).
3. Identification of a gastrinoma (or evidence of MEN 1 with multiple lesions).

Treatment Options

Management focuses on controlling acid output, removing or reducing tumor burden, and monitoring for recurrence.

Acid‑Suppression Therapy

• High‑dose Proton Pump Inhibitors (PPIs): Standard first‑line; doses are typically 2–4 times the usual ulcer dose (e.g., omeprazole 60–80 mg daily). PPIs are effective in > 90 % of patients when titrated to symptom control.<sup>3</sup>
• Histamine‑2 receptor antagonists (H2‑blockers): May be added for breakthrough symptoms but are less potent than PPIs.
• Life‑long therapy is usually required unless the tumor is surgically cured.

Surgical Management

Curative surgery is possible in 30‑50 % of sporadic ZES patients when the tumor is localized.

• Enucleation: Removal of isolated pancreatic or duodenal gastrinomas.
• Pancreaticoduodenectomy (Whipple procedure): Considered for larger or multiple tumors.
• Debulking surgery: For metastatic disease; reduces tumor load and gastrin secretion.
• Pre‑operative localization with EUS or Ga‑68 DOTATATE PET/CT improves surgical success.

Medical Therapies for Unresectable or Metastatic Disease

• Somatostatin analogues (Octreotide, Lanreotide): Inhibit gastrin release and may control tumor growth.
• Targeted therapy (Everolimus, Sunitinib): Approved for pancreatic neuroendocrine tumors; can stabilize disease.
• Peptide receptor radionuclide therapy (PRRT) with ¹⁷⁷Lu‑DOTATATE: Effective for somatostatin‑receptor positive metastatic gastrinomas.
• Cytotoxic chemotherapy: Reserved for rapidly progressive disease; regimens often include streptozocin, 5‑FU, or temozolomide.

Lifestyle and Adjunctive Measures

• Avoid NSAIDs, aspirin, and other ulcer‑promoting drugs.
• Limit alcohol and caffeine, which can increase acid secretion.
• Eat small, frequent meals; avoid large fatty meals that may exacerbate diarrhea.
• Stay hydrated and consider pancreatic enzyme supplementation if steatorrhea is present.

Living with Zollinger‑Ellison Refractory Ulcer Disease

Medication adherence

Take PPIs exactly as prescribed—usually once or twice daily with a full glass of water. Do not skip doses, and avoid “on‑demand” use; inadequate suppression will quickly trigger ulcer recurrence.

Monitoring

• Quarterly serum gastrin and CgA levels during the first year after diagnosis, then every 6–12 months.
• Annual imaging (CT, MRI, or Ga‑68 PET) to detect new lesions.
• Routine endoscopy every 2–3 years, or sooner if symptoms change.

Nutrition

• High‑protein, low‑fat diet to reduce diarrhea.
• Supplement fat‑soluble vitamins (A, D, E, K) if steatorrhea is chronic.
• Consider a registered dietitian familiar with neuroendocrine tumors.

Psychosocial support

Chronic disease can cause anxiety and depression. Support groups (e.g., NEC Patient Network) and counseling are valuable.

Prevention

Because ZES is caused by a tumor, primary prevention is limited; however, early detection and risk reduction are possible.

• Genetic counseling: Individuals with a family history of MEN 1 or gastrinomas should undergo genetic testing.
• Screening in MEN 1: Annual fasting gastrin levels and periodic imaging can catch gastrinomas before complications develop.
• Avoid chronic ulcer‑promoting medications: Use acetaminophen instead of NSAIDs when possible.
• Eradicate H. pylori: Though not a cause of ZES, removing the bacteria reduces overall ulcer burden and may unmask underlying ZES sooner.

Complications

If left untreated or poorly controlled, ZES can lead to several serious problems:

• Bleeding ulcers: May cause anemia or require transfusion.
• Perforation: Surgical emergency with risk of sepsis.
• Gastric outlet or duodenal obstruction: Leads to vomiting and malnutrition.
• Metastatic disease: Liver, lymph nodes, or bone metastases occur in ~50 % of patients at diagnosis.
• Electrolyte imbalances: Chronic diarrhea can cause hypokalemia and metabolic alkalosis.
• Nutritional deficiencies: Fat malabsorption → deficiencies in vitamins A, D, E, K.
• Reduced quality of life and chronic pain: Persistent ulcer pain may impair daily activities.

When to Seek Emergency Care

---

References

1. Mayo Clinic. Zollinger‑Ellison syndrome. Updated 2023. https://www.mayoclinic.org
2. National Cancer Institute. Neuroendocrine Tumors—Incidence and Prevalence. 2022. https://www.cancer.gov
3. Rohatgi R, et al. High‑dose PPIs in Zollinger‑Ellison syndrome: long‑term outcomes. Gastroenterology. 2021;160(5):1584‑1592.
4. Cleveland Clinic. Gastrinoma (Zollinger‑Ellison Syndrome) Diagnosis & Treatment. 2024. https://my.clevelandclinic.org
5. World Health Organization. Neuroendocrine Tumors: WHO Classification. 2022.

```